Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a placebo and active comparator controlled phase 3a study

European Urology, Supplements

Volumn 4, Issue 2, 2005, Pages 33-44

  Chapple, Christopher R ^a   Al Shukri, Salman H ^b   Gattegno, Bernard ^c   Holmes, Simon ^d   Martínez Sagarra, José M ^e   Scarpa, Roberto M ^f   Van Vierssen Trip, Oncko B ^g   Vik, Viktor ^h   Van Der Putten Slob, Ingrid ⁱ  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c HÔPITAL TENON   (France)

^d ST MARY S HOSPITAL   (United Kingdom)

^e HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^f UO Urologia ASO S Luigi O   (Italy)

^g GELDERSE VALLEI HOSPITAL   (Netherlands)

^h FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

ⁱ ASTELLAS PHARMA INC   (Japan)

Author keywords

Efficacy; Modified release formulation; Oral controlled absorption system; Placebo; Randomised controlled trial; Tamsulosin; Tolerability

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; TAMSULOSIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DYSPNEA; EJACULATION DISORDER; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SHOCK; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; SYNCOPE; TACHYCARDIA; URETHRA; URETHRA DISEASE; VERTIGO;

EID: 12344310474     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.10.010     Document Type: Article

References (26)

1. W.M. Garraway, E.B.A.W. Russell, R.J. Lee, G.N. Collins, G.B. McKelvie, and M. Hehir Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men Br J Gen Pract 43 1993 318 321
2. C.G. Chute, L.A. Panser, C.J. Girman, J.E. Oesterling, H.A. Guess, and S.J. Jacobsen The prevalence of prostatism: a population-based survey of urinary symptoms J Urol 150 1993 85 89
3. C.R. Chapple BPH Disease Management Introduction and concluding remarks Eur Urol 36 Suppl. 3 1999 1 6
4. M.J. Speakman Integrating patient risk profiles in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in clinical practice Eur Urol Suppl. 3 4 2004 18 22
5. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1999 1 13
6. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) Urology 64 6 2004 1081 1088
7. 1-adrenoceptor antagonists for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): state of the art Eur Urol Suppl 3 4 2004 23 30
8. IMS MIDA, MAT June 2002.
9. M.C. Michel, C. Korstanje, and W. Krauwinkel Cardiovascular safety of tamsulosin modified release in the fasted and fed state of elderly healthy subjects Eur Urol Suppl. 4 2 2005 9 14
10. M.C. Michel, C. Korstanje, W. Krauwinkel, and M. Kuipers The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS) Eur Urol Suppl. 4 2 2005 15 24
11. M. Sako, T. Mizumoto, A. Kajiyama, and T. Ohmura Influence of physical factors in gastrointestinal tract on acetaminophen release from controlled-release tablets in fasted dogs Int J Pharmaceut. 137 1996 225 232
12. C.R. Chapple, J. Lorenz, R. Mortensen, H. Pauthner, M.O. Reis, C.C. Schulman, and I. van der Putten-Slob Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose-response study Eur Urol Suppl. 4 2 2005 25 32
13. C.h. Chatelain, L. Denis, J.K.T. Foo, S. Khoury, J. McConnell, P. Abrams and the Members of the Committees 5th International Consultation on BPH. Recommendations of the International Scientific Committee: evaluation and treatment of lower urinary tract symptoms (LUTS) in older men C. Chatelain L. Denis K.T. Foo S. Khoury J. McConnell Benign prostatic hyperplasia 2001 Plymbridge Distributors Ltd Plymouth 519 534
14. H. Lepor for the Tamsulosin Investigator Group Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia Urology 51 1998 892 900
15. P. Narayan, and A. Tewari A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia J Urol 160 1998 1701 1706
16. 1C-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH) Br J Urol 76 1995 325 336
17. 1A-adrenoceptor antagonist. A meta-analysis of two randomised, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:155-67.
18. http://www.fda.gov/cder/approval/index.htm, accessed 27-10-2003.
19. Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ, for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41.
20. C.C. Schulman Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment Urology 62 Suppl. 3A 2003 24 33
21. C. de Mey Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being Eur Urol 34 Suppl. 2 1998 18 28
22. D.S. Coffey Controversies in the management of lower urinary tract symptoms: an overview Br J Urol 81 Suppl. 1 1998 1 5
23. M.C. Michel, L. Mehlburger, H.-U. Bressel, H. Schumacher, R.F. Schäfers, and M. Goepel Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160 1998 784 791
24. P.C. Souverein, T.P. van Staa, A.C.G. Egberts, J.J.M.C.H. de la Rosette, C. Cooper, and H.G.M. Leufkens Use of α-blockers and the risk of hip/femur fractures J Intern Med 254 2003 548 554
25. R.B. Stewart, M.T. Moore, F.E. May, R.G. Marks, and W.E. Hale Nocturia: a risk factor for falls in the elderly J Am Geriatr Soc 40 1992 1217 1220
26. C.C. Schulman, R. Asplund, F. Desgrandchamps, and U. Jonas The impact of nocturia on health status and quality of life in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) Eur Urol Suppl. 4 2 2005 1 8